Clinical & experimental findings

Human randomized studyAbstract inspected

An interim analysis of a multi-year Alzheimer disease trial (113 of a planned 210 patients with Alzheimer disease plus ischemic cerebrovascular injury, followed for two years) found less deterioration in cognitive, functional and behavioral measures with choline alphoscerate added to donepezil than with donepezil plus placebo. It did not test Alpha-GPC alone, and it did not assess cognitive enhancement in healthy people.^[1]

Combination treatment, selected disease population and interim analysis; no healthy-person or single-agent inference.
The same research group has published at least four further interim analyses of this trial on different outcome domains (apathy 2012/2015, behavioral disturbances 2017, brain-volume imaging 2020) and registered a separate 2024 protocol for choline alphoscerate alone in mild cognitive dysfunction; no completed final ASCOMALVA trial report was located in this search, so this remains an interim, not final, result.
Abstract-checked; no qualified clinical review.

Inspection history

Clinical review: not reviewed by a qualified clinician.

2026-09-08 · Prior batch record retained as unverified historical input pending fresh review.

2026-09-09 · nootropic batch: reopened source(s) via NCBI E-utilities / PMC Open Access; verified and refined with precise numbers/limitations from the source.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Narrowly supported passages published with study/product limits; remaining inherited assertions withheld from established-fact displays.

Not a comprehensive systematic review. Original monograph topics beyond the individual published claims—including monitoring schedules, contraindication lists, recovery assurances and detailed mechanisms—remain unverified.
No qualified clinician has reviewed these claims. Long-term outcomes and all marketed formulations have not been fully assessed.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.
Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. J Alzheimers Dis. 2014;42 Suppl 3:S281-8. DOI: 10.3233/JAD-140150. 2014. PMID:24898643 · DOI:10.3233/JAD-140150 Abstract only.
Inspected location: PubMed/MEDLINE abstract (full Background/design/Results text) via NCBI E-utilities efetch
Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts

Fresh PubMed EUtils retrieval for inherited lead PMID 24898643; identity, abstract and linked corrections checked where an abstract existed.
https://pubmed.ncbi.nlm.nih.gov/24898643/ — abstract; PubMed abstract: Results: two-year interim cognitive/functional comparisons; Methods: donepezil combination and cerebrovascular Alzheimer population

View this compound in the research library →

Related records in this class

Grouped under Other compounds for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.